Tardive Dyskinesia

Total Page:16

File Type:pdf, Size:1020Kb

Tardive Dyskinesia Tardive Dyskinesia Tardive Dyskinesia Checklist The checklist below can be used to help determine if you or someone you know may have signs associated with tardive dyskinesia and other movement disorders. Movement Description Observed? Rhythmic shaking of hands, jaw, head, or feet Yes Tremor A very rhythmic shaking at 3-6 beats per second usually indicates extrapyramidal symptoms or side effects (EPSE) of parkinsonism, even No if only visible in the tongue, jaw, hands, or legs. Sustained abnormal posture of neck or trunk Yes Dystonia Involuntary extension of the back or rotation of the neck over weeks or months is common in tardive dystonia. No Restless pacing, leg bouncing, or posture shifting Yes Akathisia Repetitive movements accompanied by a strong feeling of restlessness may indicate a medication side effect of akathisia. No Repeated stereotyped movements of the tongue, jaw, or lips Yes Examples include chewing movements, tongue darting, or lip pursing. TD is not rhythmic (i.e., not tremor). These mouth and tongue movements No are the most frequent signs of tardive dyskinesia. Tardive Writhing, twisting, dancing movements Yes Dyskinesia of fingers or toes Repetitive finger and toe movements are common in individuals with No tardive dyskinesia (and may appear to be similar to akathisia). Rocking, jerking, flexing, or thrusting of trunk or hips Yes Stereotyped movements of the trunk, hips, or pelvis may reflect tardive dyskinesia. No There are many kinds of abnormal movements in individuals receiving psychiatric medications and not all are because of drugs. If you answered “yes” to one or more of the items above, an evaluation by a psychiatrist or neurologist skilled in movement disorders may be warranted to determine the type of disorder and best treatment options. If you answered “no” to the items above, an examination should be conducted by a mental health care provider every six to 12 months while the individual is taking an antipsychotic medication. (Marder et al, Am J Psychiatry 2004). The Abnormal Involuntary Movement Scale (AIMS) exam is designed to assess movements associated with TD. Ask your doctor for regular AIMS exams. Early detection is the best approach. A copy of an AIMS exam can be found at the following link: www.cqaimh.org/pdf/tool_aims.pdf NAMI • The National Alliance on Mental Illness • 1 (800) 950-NAMI • www.nami.org 3803 N. Fairfax Drive, Suite 100, Arlington, VA 22203.
Recommended publications
  • Rest Tremor Revisited: Parkinson's Disease and Other Disorders
    Chen et al. Translational Neurodegeneration (2017) 6:16 DOI 10.1186/s40035-017-0086-4 REVIEW Open Access Rest tremor revisited: Parkinson’s disease and other disorders Wei Chen1,2, Franziska Hopfner2, Jos Steffen Becktepe2 and Günther Deuschl1,2* Abstract Tremor is the most common movement disorder characterized by a rhythmical, involuntary oscillatory movement of a body part. Since distinct diseases can cause similar tremor manifestations and vice-versa,itischallengingtomakean accurate diagnosis. This applies particularly for tremor at rest. This entity was only rarely studied in the past, although a multitude of clinical studies on prevalence and clinical features of tremor in Parkinson’s disease (PD), essential tremor and dystonia, have been carried out. Monosymptomatic rest tremor has been further separated from tremor-dominated PD. Rest tremor is also found in dystonic tremor, essential tremor with a rest component, Holmes tremor and a few even rarer conditions. Dopamine transporter imaging and several electrophysiological methods provide additional clues for tremor differential diagnosis. New evidence from neuroimaging and electrophysiological studies has broadened our knowledge on the pathophysiology of Parkinsonian and non-Parkinsonian tremor. Large cohort studies are warranted in future to explore the nature course and biological basis of tremor in common tremor related disorders. Keywords: Tremor, Parkinson’s disease, Essential tremor, Dystonia, Pathophysiology Background and clinical correlates of tremor in common tremor re- Tremor is defined as a rhythmical, involuntary oscillatory lated disorders. Some practical clinical cues and ancillary movement of a body part [1]. Making an accurate diagnosis tests for clinical distinction are found [3]. Besides, accu- of tremor disorders is challenging, since similar clinical mulating structural and functional neuroimaging, as well entities may be caused by different diseases.
    [Show full text]
  • Diagnostic Clues in Multiple System Atrophy
    DO I:10.4274/Tnd.82905 Case Report / Olgu Sunumu Diagnostic Clues in Multiple System Atrophy: A Case Report and Literature Review Multisistem Atrofi Tanısında İpuçları: Bir Olgu Sunumu ve Literatürün Gözden Geçirilmesi Mehmet Yücel, Oğuzhan Öz, Hakan Akgün, Semai Bek, Tayfun Kaşıkçı, İlter Uysal, Yaşar Kütükçü, Zeki Odabaşı Gülhane Military Medical Academy, Ankara, Turkey Sum mary Multiple system atrophy (MSA) is an adult-onset, sporadic, progressive neurodegenerative disease. Based on the consensus criteria, patients with MSA are clinically classified into cerebellar (MSA-C) and parkinsonian (MSA-P) subtypes. In addition to major diagnostic criteria including poor response to levodopa, and presence of pyramidal or cerebellar signs (ataxia) or autonomic failure, certain clinical features or ‘‘red flags’’ may raise the clinical suspicion for MSA. In our case report we present a 67-year-old female patient admitted to our hospital due to inability to walk, with poor response to levodopa therapy, whose neurological examination revealed severe Parkinsonism, ataxia and who fulfilled all criteria for MSA, as rarely seen in clinical practice.(Turkish Journal of Neurology 2013; 19:28-30) Key Words: Multiple system atrophy, autonomic failure, diagnostic criteria Özet Multisistem atrofi (MSA) erişkin dönemde başlayan, ilerleyici, nedeni bilinmeyen sporadik nörodejeneratif bir hastalıktır. MSA kabul görmüş tanı kriterlerine göre klinik olarak serebellar (MSA-C) ve parkinsoniyen (MSA-P) alt tiplerine ayrılmaktadır. Düşük levadopa yanıtı, piramidal, serebellar bulguların (ataksi) ya da otonomik bozukluk olması gibi majör tanı kriterlerininin yanında “red flags” olarak isimlendirilen belirgin klinik bulgular ya da uyarı işaretlerinin olması MSA tanısı için klinik şüpheyi oluşturmalıdır. Olgu sunumunda 67 yaşında yürüyememe şikayeti ile polikliniğimize müracaat eden ve levadopa tedavisine düşük yanıt gösteren ciddi parkinsonizm bulguları ile ataksi bulunan kadın hasta MSA tanı kriterlerini tam olarak karşıladığı ve klinik pratikte nadir görüldüğü için sunduk.
    [Show full text]
  • Tourette's Syndrome
    Tourette’s Syndrome CHRISTOPHER KENNEY, MD; SHENG-HAN KUO, MD; and JOOHI JIMENEZ-SHAHED, MD Baylor College of Medicine, Houston, Texas Tourette’s syndrome is a movement disorder most commonly seen in school-age children. The incidence peaks around preadolescence with one half of cases resolving in early adult- hood. Tourette’s syndrome is the most common cause of tics, which are involuntary or semi- voluntary, sudden, brief, intermittent, repetitive movements (motor tics) or sounds (phonic tics). It is often associated with psychiatric comorbidities, mainly attention-deficit/hyperac- tivity disorder and obsessive-compulsive disorder. Given its diverse presentation, Tourette’s syndrome can mimic many hyperkinetic disorders, making the diagnosis challenging at times. The etiology of this syndrome is thought to be related to basal ganglia dysfunction. Treatment can be behavioral, pharmacologic, or surgical, and is dictated by the most incapacitating symp- toms. Alpha2-adrenergic agonists are the first line of pharmacologic therapy, but dopamine- receptor–blocking drugs are required for multiple, complex tics. Dopamine-receptor–blocking drugs are associated with potential side effects including sedation, weight gain, acute dystonic reactions, and tardive dyskinesia. Appropriate diagnosis and treatment can substantially improve quality of life and psychosocial functioning in affected children. (Am Fam Physician. 2008;77(5):651-658, 659-660. Copyright © 2008 American Academy of Family Physicians.) ▲ Patient information: n 1885, Georges Gilles de la Tourette normal context or in inappropriate situa- A handout on Tourette’s described the major clinical features tions, thus calling attention to the person syndrome, written by the authors of this article, is of the syndrome that now carries his because of their exaggerated, forceful, and provided on p.
    [Show full text]
  • Neuroleptic Malignant Syndrome: a Case of Unknown Causation and Unique Clinical Course
    Open Access Case Report DOI: 10.7759/cureus.14113 Neuroleptic Malignant Syndrome: A Case of Unknown Causation and Unique Clinical Course Brooke J. Olson 1 , Mohan S. Dhariwal 1 1. Internal Medicine, Medical College of Wisconsin, Milwaukee, USA Corresponding author: Brooke J. Olson, [email protected] Abstract Neuroleptic malignant syndrome (NMS) is a rare, potentially lethal syndrome known to be related to the initiation of dopamine antagonist medications or rapid withdrawal of dopaminergic medications. It is a diagnosis of exclusion with a known sequela of symptoms, but not all patients experience these characteristic symptoms making it difficult at times to diagnose and treat. Herein, we present a unique case of NMS with unclear etiology and a unique clinical course. Our case report also raises the question of whether or not adjusting doses of previously prescribed neuroleptic medications can provoke NMS, providing valuable information for providers treating these complex patients. Categories: Internal Medicine, Neurology, Psychiatry Keywords: neuroleptics, neuroleptic malignant syndrome, adverse drug reaction, neuropharmacology, neuroleptic medications, psychotic disorder, dopamine, antipsychotic medications Introduction Neuroleptic malignant syndrome (NMS) is a rare, potentially lethal syndrome known to be related to the initiation of dopamine antagonist medications or rapid withdrawal of dopaminergic medications. The incidence of this uncommon condition ranges from 0.02% to 3% of patients taking antipsychotic medications, most commonly affecting young men given high-dose antipsychotics [1]. While easily recognizable when all classic symptoms are present, the heterogeneity of its clinical course makes this syndrome difficult to identify, commonly left as a diagnosis of exclusion [2]. With this case report, we present a diagnosis of NMS with unclear etiology and unique clinical course.
    [Show full text]
  • Clinical Manifestations of Essential Tremor
    Journial of Neurology, Neurosurgery, and Psychiatry, 1972, 35, 365-372 J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.35.3.365 on 1 June 1972. Downloaded from Clinical manifestations of essential tremor EDMUND CRITCHLEY From the Royal Infirmary, Preston SUMMARY A clinical study of 42 patients with essential tremor is presented. In the case of 12 patients the family history strongly suggested an autosomal dominant mode of transmission, in four the mode of inheritance was indeterminate, and the remaining 26 patients were sporadic cases without an established genetic basis. The tremor involved the upper extremities in 41 patients, the head in 25, lower limbs in 15, and trunk in two. Seven patients showed involvement of speech. Variations were found in the speed and regularity of the tremor. Leg involvement took a variety of forms: (1) direct involvement by tremor; (2) a painful limp associated with forearm tremor; (3) associated dyskinetic movements; (4) ataxia; (5) foot clubbing; and (6) evidence of peroneal muscular atrophy. Several minor symptoms hyperhidrosis, cramps, dyskinetic movements, and ataxia-were associated with essential tremor. Other features were linked phenotypically to the ataxias and system degenerations. Apart from minor alterations in tone, expression, and arm swing, features of Parkinsonism were notably absent. Protected by copyright. Essential tremor has been recognized as an or- much variation. It is occasionally present at rest ganic peculiarity of the nervous system, mimick- and inhibited by action, but is more usually de- ing neurotic and neural disorders with equal creased or absent at rest and present on volun- facility. Many synonyms-for example, benign, tary increase in muscle tonus, as in holding a limb hereditary, and senile tremor-describe its varied in a definite position (static, sustained-postural presentation.
    [Show full text]
  • Tourette-Like Syndrome Following Low Dose Short-Term Neuroleptic Treatment Samarthji Lai and Esam Alansari
    LE JOURNAL CANADIEN DES SCIENCES NEUROLOGIQUES Tourette-like Syndrome Following Low Dose Short-term Neuroleptic Treatment Samarthji Lai and Esam AlAnsari ABSTRACT: A Tourette-like syndrome (TLS) may occur after long-term neuroleptic treatment. A review of 11 cases reported in the literature is given. We describe the onset of a TLS in a 13-year old boy with childhood schizophrenia after short term, low-dose treatment with thioridazine. The syndrome resolved 5 months after neuroleptic withdrawal. Subsequent exposure to neuroleptics (mainly perphenazine) induced a recurrence of motor tics and involuntary vocalizations which resolved on drug discontinuation. Awareness that neuroleptics may induce a TLS may lead to prompt recognition and avoidance of labelling the manifestations as symptoms of the underlying psychosis or attention-seeking behaviour. RESUME: Une syndrome analogue a ce de Gilles de la Tourette suivant le traitement prolonge par des neuroleptiques Un syndrome analogue au syndrome de Gilles de la Tourette peut survenir a la suite d'un traitement prolong^ par les neuroleptiques. Nous faisons une revue de 11 cas rapportes dans la litterature et nous decrivons le cas d'un jeune garcon de 13 ans souffrant de schizophrenic de I'enfance ayant presente un tel syndrome apres un traitement a la thioridazine a faible dose sur une courte periode de temps. Le syndrome s'est dissipe, 5 mois apres le retrait du neuroleptique. L'exposition subsequente a des neuroleptiques (surtout a la perphenazine), provoqua une reapparition des tics moteurs et des vocalisations involontaires qui disparurent a I'arret de la the>apie. La connaissance du fait que les neuroleptiques peuvent induire un syndrome analogue au Gilles de la Tourette peut conduire a un diagnostic rapide et eviter que ces manifestations soient etiquettees comme des symptomes de la psychose sous-jacente ou comme un comportement visant a attirer l'attention.
    [Show full text]
  • Part Ii – Neurological Disorders
    Part ii – Neurological Disorders CHAPTER 14 MOVEMENT DISORDERS AND MOTOR NEURONE DISEASE Dr William P. Howlett 2012 Kilimanjaro Christian Medical Centre, Moshi, Kilimanjaro, Tanzania BRIC 2012 University of Bergen PO Box 7800 NO-5020 Bergen Norway NEUROLOGY IN AFRICA William Howlett Illustrations: Ellinor Moldeklev Hoff, Department of Photos and Drawings, UiB Cover: Tor Vegard Tobiassen Layout: Christian Bakke, Division of Communication, University of Bergen E JØM RKE IL T M 2 Printed by Bodoni, Bergen, Norway 4 9 1 9 6 Trykksak Copyright © 2012 William Howlett NEUROLOGY IN AFRICA is freely available to download at Bergen Open Research Archive (https://bora.uib.no) www.uib.no/cih/en/resources/neurology-in-africa ISBN 978-82-7453-085-0 Notice/Disclaimer This publication is intended to give accurate information with regard to the subject matter covered. However medical knowledge is constantly changing and information may alter. It is the responsibility of the practitioner to determine the best treatment for the patient and readers are therefore obliged to check and verify information contained within the book. This recommendation is most important with regard to drugs used, their dose, route and duration of administration, indications and contraindications and side effects. The author and the publisher waive any and all liability for damages, injury or death to persons or property incurred, directly or indirectly by this publication. CONTENTS MOVEMENT DISORDERS AND MOTOR NEURONE DISEASE 329 PARKINSON’S DISEASE (PD) � � � � � � � � � � �
    [Show full text]
  • Clinical Study Clinic-Based Retrospective Analysis of Psychopharmacology for Behavior in Fragile X Syndrome
    Hindawi Publishing Corporation International Journal of Pediatrics Volume 2012, Article ID 843016, 11 pages doi:10.1155/2012/843016 Clinical Study Clinic-Based Retrospective Analysis of Psychopharmacology for Behavior in Fragile X Syndrome Elizabeth Berry-Kravis,1, 2 Allison Sumis,1 Crystal Hervey,1 and Shaguna Mathur1 1 Department of Pediatrics, RUSH University Medical Center, Chicago, IL 60612, USA 2 Departments of Neurology and Biochemistry, RUSH University Medical Center, Chicago, IL 60612, USA Correspondence should be addressed to Elizabeth Berry-Kravis, elizabeth [email protected] Received 12 December 2011; Revised 10 April 2012; Accepted 16 April 2012 Academic Editor: Sheffali Gulati Copyright © 2012 Elizabeth Berry-Kravis et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Fragile X syndrome (FXS) is associated with behavior that limits functioning, including distractibility, hyperactivity, impulsivity, hyperarousal, anxiety, mood dysregulation, and aggression. Medication response and side effect data were reviewed retrospectively for 257 patients (age 14 ± 11 years, range 4–60 years, 203 M, 54 F) attending an FXS clinic. Treatment success rates were defined as the percentage of positive response in the form of documented clinical report of improvement in the behavior(s) being targeted over at least a 6-month period on the medication, without side effects requiring medication discontinuance, while failures were defined as discontinuance of medication due to lack of clinical effectiveness or side effects. Success rate for treatment of targeted behaviors with trials of individual medications was 55% for stimulants, 53% for antidepressants, 62% for alpha2-agonists, and 54% for antipsychotics.
    [Show full text]
  • Oromandibular Dyskinesia As the Initial Manifestation of Late-Onset Huntington Disease
    online © ML Comm Journal of Movement Disorders 2011;4:75-77 CASE REPORT pISSN 2005-940X / eISSN 2093-4939 Oromandibular Dyskinesia as the Initial Manifestation of Late-Onset Huntington Disease Dong-Seok Oh Huntington’s disease (HD) is a neurodegenerative disorder characterized by a triad of choreo- Eun-Seon Park athetosis, dementia and dominant inheritance. The cause of HD is an expansion of CAG tri- Seong-Min Choi nucleotide repeats in the HD gene. Typical age at onset of symptoms is in the 40s, but the dis- Byeong-Chae Kim order can manifest at any time. Late-onset (≥ 60 years) HD is clinically different from other Myeong-Kyu Kim adult or juvenile onset HD and characterized by mild motor problem as the initial symptoms, Ki-Hyun Cho shorter disease duration, frequent lack of family history, and relatively low CAG repeats ex- pansion. We report a case of an 80-year-old female with oromandibular dyskinesia as an initial Department of Neurology, manifestation of HD and 40 CAG repeats. ; : Chonnam National University Journal of Movement Disorders 2011 4 75-77 Medical School, Gwangju, Korea Key Words: Late-onset Huntington disease, Intermediate CAG repeats, Oromandibular dyskinesia. Huntington’s disease (HD) is a well known cause of chorea, characterized by a triad of cho- reoathetosis, dementia and dominant inheritance.1 The typical age of onset for adult-onset HD is between the ages of 30 and 50,2 but the disorder can manifest at any time between infancy and senescence. The cause of HD is expansion of CAG trinucleotide repeats, 35 or greater, in the coding region of the Huntington gene on chromosome 4.
    [Show full text]
  • The Paroxysmal Dyskinesias
    The Paroxysmal Dyskinesias Kailash Bhatia Institute of Neurology Queen Square, London UK Note: 2008 Course Slides The Paroxysmal Dyskinesias A heterogeneous and rare group of disorders characterised by recurrent brief episodes of abnormal involuntary movements (Interictally the patient is usually normal) Movements may be chorea, ballism, dystonia, or a combination Diagnosis is often missed Paroxysmal Dyskinesias -Historical Aspects • Gowers (1885)- called it epilepsy! • Mount and Reback (1940)- first clear description 23 yr/male with an AD inherited condition, attacks of choreo- athetosis lasting 5 mins to hours, provoked by alcohol, coffee, tea, fatigue and smoking • “Paroxysmal dystonic choreoathetosis” (PDC) • Other similar families- (Forsmann 1961, Lance 1963, Richard and Barnet, 1968, Fink et al, 1997, Jarman et al, 2000) Paroxysmal dyskinesias -Historical aspects •Kertesz (1967) – new term (Paroxysmal “kinesigenic” choreoathetosis: An entity within the paroxysmal choreo-athetosis syndrome. Description of 10 cases including 1 autopsied) • Attacks were induced by sudden movement (i.e. kinesigenic ) and were very brief • Response to antiepileptics Paroxysmal Dyskinesias- Historical Aspects • Lance 1977 - a new form of paroxysmal dyskinesia in a family • Affected members had attacks of dystonia lasting 5-30 minutes provoked by prolonged exercise (not sudden movement) • Paroxysmal exercise-induced dystonia (PED) Paroxysmal Dyskinesias- Classification Lance (1977)- “the time factor” • PKC-sudden, brief (secs-5mins), movement induced attacks
    [Show full text]
  • Dyskinesia in Parkinson's Disease
    Last Updated March 6, 2018 DYSKINESIA IN PARKINSON’S DISEASE The meaning of dyskinesia comes from dys, referring to “not correct”, and kinesia referring to “movement”. Dyskinesia is characterized by abnormal, involuntary wriggling movements that some describe as random dance-like motions. These movements are different from the common Parkinson’s disease tremor. Dyskinesia can affect part of the body or the entire body, including the legs, arms, trunk, head, face, mouth and tongue. Causes of Dyskinesia It is important to note that not all people living with PD will experience dyskinesia, and although dyskinesia is not a direct symptom of Parkinson’s disease (PD), it can be a side effect of medication prescribed to treat PD. As PD progresses, there are changes in how the brain is able to store and release dopamine. This means that over time, people with PD are more likely to experience dyskinesia no matter how long they have been on treatment. Dyskinesia occurs most commonly during the peak effects of an individual taking levodopa/carbidopa, called peak-dose dyskinesia. It can also occur at the start of a dose when it is beginning to take effect (wearing “on”) and similarly at the end of the dose when the effects of the medication are starting to wear off (wearing “off”). Dyskinesia may also fluctuate in an individual due to stress. Dystonia may also occur during these on/off times (refer to help sheet on dystonia). If you are experiencing dyskinesia, be sure to record when it occurs during your medication cycle as this information can be helpful for your healthcare team.
    [Show full text]
  • Current P SYCHIATRY
    CP_1006_Erickson.FinalREV3 9/21/06 8:59 AM Page 80 Current p SYCHIATRY Managing maladaptive behaviors in fragile X patients Psychotropics can improve hyperactivity, anxiety, and aggression Craig A. Erickson, MD Fellow, child and adolescent psychiatry ® Dowden Health Media Kimberly A. Stigler, MD Copyright Assistant professor For personalDavid use J. Posey, only MD Associate professor Christopher J. McDougle, MD Albert E. Sterne Professor and chairman Department of psychiatry Indiana University School of Medicine Christian Sarkine Autism Treatment Center James Whitcomb Riley Hospital for Children Indianapolis sychotropics1,2 are used to manage mal- P adaptive and interfering behaviors in 70% of patients with fragile X syndrome (FXS), the leading cause of hereditary mental retardation. Treatment tends to follow a developmental course: • In children, stimulants and alpha-2 agonists are used for attention-deficit/hyperactivity disorder (ADHD)-like symptoms. • In adolescents and adults, selective sero- tonin reuptake inhibitors (SSRIs) are used for anxiety/repetitive phenomena and second-generation antipsychotics (SGAs) for irritability. © images.com / Veer 80 VOL. 5, NO. 10 / OCTOBER 2006 For mass reproduction, content licensing and permissions contact Dowden Health Media. CP_1006_Erickson.FinalREV2 9/20/06 2:44 PM Page 81 Current p SYCHIATRY This course—which is often effective—is Box based primarily on anecdotal descriptions and on Fragile X syndrome’s genetic rationales borrowed from studies of ADHD, and behavioral features obsessive-compulsive disorder (OCD), and autis- tic disorder/related pervasive developmental dis- The term “fragile X” describes how the 3 orders (PDDs). Disease-modifying agents to tar- X chromosome of affected individuals get the underlying brain dysregulation inherent fractures in a folate-deprived medium.
    [Show full text]